fda compounding semaglutide news october 2025 Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots Diabetes advocacy group discourages use

Clinical trial data from the STEP 1 and SURMOUNT-1 trials show that patients typically achieve 1015% total body weight loss with semaglutide 2.4 mg weekly (Wegovy) and 1520% with tirzepatide 1015 mg weekly (Zepbound) over 1218 months

Several synthetic strategies have been developed to obtain polymyxins

These studies showed (with statistical significance) that after lipedema reduction surgery patients experienced: A significant reduction in pain, sensitivity to touch and discomfort a

What If the First Medication Does Not Work Not every patient has the same response to the same medication

Obesity is a major driver of US health care costs, totaling almost $173 billion annually, according to the CDC in 2024

Zepbound will drop to $346 a month compared to its typical $1,086 per month